GW 473178
Alternative Names: 473178Latest Information Update: 02 Aug 2023
At a glance
- Originator GlaxoSmithKline
- Class
- Mechanism of Action Thrombin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Atrial fibrillation; Venous thrombosis
Most Recent Events
- 16 Dec 2003 Discontinued - Phase-I for Atrial fibrillation in USA (unspecified route)
- 16 Dec 2003 Discontinued - Phase-I for Venous thrombosis in USA (unspecified route)
- 18 Nov 2002 Phase-I clinical trials in Atrial fibrillation in USA (unspecified route)